Completed PHASE2 INTERVENTIONAL NCT00003352

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)

Sponsor: NSABP Foundation Inc

Conditions Breast Cancer

Interventions Adriamycin Taxotere cyclophosphamide

Updated 7 times since 2017 Last updated: Dec 10, 2012 Started: Jun 30, 1998 Primary completion: Sep 30, 2000 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by NSABP Foundation Inc and has accumulated 7 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NSABP Foundation Inc
National Cancer Institute (NCI)

Data source: NSABP Foundation Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albany, United States , Albuquerque, United States , Allentown, United States , Ann Arbor, United States , Atlanta, United States , Augusta, United States , Baltimore, United States , Bangor, United States , Bethesda, United States and 119 more locations